Published in Am J Hum Genet on June 01, 1989
The red-green visual pigment gene region in adrenoleukodystrophy. Am J Hum Genet (1990) 0.96
Ophthalmic manifestations of inherited neurodegenerative disorders. Nat Rev Neurol (2014) 0.92
Adrenoleukodystrophy: a complex chromosomal rearrangement in the Xq28 red/green-color-pigment gene region indicates two possible gene localizations. Am J Hum Genet (1991) 0.90
Chromosomal rearrangement segregating with adrenoleukodystrophy: a molecular analysis. Proc Natl Acad Sci U S A (1993) 0.79
Chromosomal rearrangement segregating with adrenoleukodystrophy: associated changes in color vision. Proc Natl Acad Sci U S A (1993) 0.77
DNA diagnosis of X-linked adrenoleukodystrophy. J Inherit Metab Dis (1995) 0.75
Molecular genetics of inherited variation in human color vision. Science (1986) 5.28
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
Contiguous gene syndromes: a component of recognizable syndromes. J Pediatr (1986) 3.18
Further studies on acquired deficiency of color discrimination. J Opt Soc Am (1963) 2.68
Genetic linkage between X-chromosome markers and bipolar affective illness. Nature (1987) 2.44
Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology (1977) 2.19
Tandem array of human visual pigment genes at Xq28. Science (1988) 1.91
Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol (1984) 1.83
Proposals for scoring and assessing the 100-Hue test. Vision Res (1970) 1.67
Assignment of the gene for dyskeratosis congenita to Xq28. Hum Genet (1986) 1.62
Frequent alterations of visual pigment genes in adrenoleukodystrophy. Am J Hum Genet (1988) 1.32
Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A (1988) 1.26
Linkage of adrenoleukodystrophy to a polymorphic DNA probe. Ann Neurol (1987) 1.20
Emery-Dreifuss muscular dystrophy: localisation to Xq27.3----qter confirmed by linkage to the factor VIII gene. J Med Genet (1986) 1.06
Lignoceroyl-CoASH ligase: enzyme defect in fatty acid beta-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Lett (1986) 1.05
Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem Biophys Res Commun (1988) 1.04
Characterization of six partial deletions in the low-density-lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH). Am J Hum Genet (1988) 1.02
Electroretinograms in carriers of blue cone monochromatism. Am J Ophthalmol (1986) 0.94
The adrenoleukodystrophies. Crit Rev Neurobiol (1987) 0.89
Identification of female carriers of adrenoleukodystrophy. J Pediatr (1983) 0.87
Colour vision abnormalities in multiple sclerosis. Can J Neurol Sci (1987) 0.85
On quantifying the bipolarity and axis of the Farnsworth-Munsell 100-Hue test. Invest Ophthalmol Vis Sci (1987) 0.85
Heterozygote detection in X-linked recessive incomplete achromatopsia. Ophthalmic Paediatr Genet (1988) 0.82
Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex (2000) 3.69
Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A (1981) 2.83
Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. Nat Genet (1995) 2.62
MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol (1995) 2.42
A unified nomenclature for peroxisome biogenesis factors. J Cell Biol (1996) 2.25
Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol (1993) 2.07
Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol (1999) 2.06
Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology (2003) 1.92
Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol (1984) 1.83
Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology (1981) 1.81
Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology (2005) 1.77
Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A (1984) 1.75
Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol (2001) 1.71
Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol (1980) 1.71
Hyperornithinemia, hyperammonemia, and homocitrullinuria. A new disorder of amino acid metabolism associated with myoclonic seizures and mental retardation. Am J Dis Child (1969) 1.65
The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. EMBO J (1996) 1.62
The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis. N Engl J Med (1984) 1.56
Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet (1986) 1.47
Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet (1998) 1.47
Complementation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. Hum Genet (1992) 1.46
ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat (2001) 1.45
Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. Nat Genet (1997) 1.44
Identification of three distinct peroxisomal protein import defects in patients with peroxisome biogenesis disorders. J Cell Sci (1995) 1.40
Cerebro-hepato-renal (Zellweger) syndrome and neonatal adrenoleukodystrophy: similarities in phenotype and accumulation of very long chain fatty acids. Johns Hopkins Med J (1982) 1.39
Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science (1984) 1.39
Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol (1998) 1.35
Frequent alterations of visual pigment genes in adrenoleukodystrophy. Am J Hum Genet (1988) 1.32
Metabolic control of peroxisome abundance. J Cell Sci (1999) 1.31
Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders. Am J Hum Genet (1998) 1.31
Standardization of complementation grouping of peroxisome-deficient disorders and the second Zellweger patient with peroxisomal assembly factor-1 (PAF-1) defect. Am J Hum Genet (1993) 1.29
The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol (1992) 1.27
Adrenoleukodystrophy: studies of the phenotype, genetics and biochemistry. Johns Hopkins Med J (1980) 1.23
Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res (1984) 1.21
Linkage of adrenoleukodystrophy to a polymorphic DNA probe. Ann Neurol (1987) 1.20
A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A (1997) 1.20
Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol (2001) 1.19
Apparent biochemical homozygosity in two obligatory heterozygotes for metachromatic leukodystrophy. J Pediatr (1976) 1.19
Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol (2000) 1.17
Solubilization and partial purification of steroid sulfatase from rat liver: characterization of estrone sulfatase. Arch Biochem Biophys (1976) 1.16
Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies. Science (1985) 1.15
Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol (2001) 1.15
Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim Biophys Acta (1975) 1.15
Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem Res (1999) 1.11
Identification of a fatty acid delta6-desaturase deficiency in human skin fibroblasts. J Lipid Res (2001) 1.10
Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet (1995) 1.08
Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. Am J Hum Genet (1999) 1.08
Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science (1972) 1.08
Hyperuricemia in Down's syndrome. J Clin Endocrinol Metab (1968) 1.07
Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab (1999) 1.07
A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol (1987) 1.06
Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochem Biophys Res Commun (1981) 1.06
Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant (2000) 1.05
Familial X-linked Addison disease as an expression of adrenoleukodystrophy (ALD): elevated C26 fatty acid in cultured skin fibroblasts. Neurology (1982) 1.05
High concentration of hexacosanoate in cultured skin fibroblast lipids from adrenoleukodystrophy patients. Biochem Biophys Res Commun (1978) 1.05
Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry (1996) 1.05
Brain lipids, proteolipids, and free amino acids in maple syrup urine disease. J Neurochem (1966) 1.03
Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurology (2001) 1.03
New approaches in peroxisomal disorders. Dev Neurosci (1987) 1.03
Development of myelin in inherited disorders of amino acid metabolism. Arch Neurol (1968) 1.02
Peroxisome assembly mutations in humans: structural heterogeneity in Zellweger syndrome. J Cell Physiol (1992) 1.01
Solvent vapor abuse leukoencephalopathy. Comparison to adrenoleukodystrophy. J Neuropathol Exp Neurol (1994) 1.00
Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol (1982) 1.00
Peroxisomal straight-chain Acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis. J Biol Chem (2001) 1.00
Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol (2001) 0.99
Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis (1986) 0.99
X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol (2000) 0.99
Stimulation of acid ceramidase activity by saposin D. Arch Biochem Biophys (1994) 0.99
The peroxisome deficient PEX2 Zellweger mouse: pathologic and biochemical correlates of lipid dysfunction. J Mol Neurosci (2001) 0.99
A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects. Eur J Pediatr (1985) 0.97
Neuroimaging studies in Rett syndrome. Brain Dev (2001) 0.96
Modification of the schedule of myelination in the rat by early nutritional deprivation. Pediatrics (1966) 0.96
A fibroblast cell line defective in alkyl-dihydroxyacetone phosphate synthase: a novel defect in plasmalogen biosynthesis. Proc Natl Acad Sci U S A (1997) 0.95
Non-infantile neuronopathic Gaucher's disease: a clinicopathologic study. Neurology (1983) 0.95
Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts. J Pediatr (1976) 0.94
The nosology of mental retardation: including the report of a survey of 1378 mentally retarded individuals at the Walter E. Fernald State School. Birth Defects Orig Artic Ser (1971) 0.94
Peroxisomal disorders. J Pediatr (1986) 0.94
Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol (1985) 0.94
Rett syndrome--natural history in 70 cases. Am J Med Genet Suppl (1986) 0.94
A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. Am J Med Genet (1985) 0.94
Adrenoleukodystrophy: evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem Biophys Res Commun (1980) 0.93
MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy. Neurology (2003) 0.93
Cytosolic compartmentalization of hepatic alanine:glyoxylate aminotransferase in patients with aberrant peroxisomal biogenesis and its effect on oxalate metabolism. J Inherit Metab Dis (1994) 0.93
Neonatal adrenoleukodystrophy: clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females. Am J Pathol (1982) 0.93
Bone marrow transplant in adrenoleukodystrophy. Neurology (1984) 0.93
Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy. Neurology (2005) 0.92
Branched-chain and odd-numbered fatty acids and aldehydes in the nervous system of a patient with deranged vitamin B 12 metabolism. J Lipid Res (1973) 0.92
Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci (1992) 0.92
Striated adrenocortical cells in cerebro-hepato-renal (Zellweger) syndrome. Virchows Arch A Pathol Anat Histopathol (1983) 0.91
Role of lysosomal acid ceramidase in the metabolism of ceramide in human skin fibroblasts. Arch Biochem Biophys (1981) 0.91
Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies. Ann Neurol (1995) 0.91
The peroxin Pex6p gene is impaired in peroxisomal biogenesis disorders of complementation group 6. J Hum Genet (2001) 0.91
Preliminary observations on the occurrence of cholesterol sulfate in man. Biochim Biophys Acta (1966) 0.91
Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol (1994) 0.91
Adrenoleukodystrophy: clinical and biochemical manifestations in carriers. Neurology (1984) 0.90
Ocular histopathologic studies of neonatal and childhood adrenoleukodystrophy. Am J Ophthalmol (1983) 0.90
Phenotypic variability in siblings with Farber disease. J Pediatr (1984) 0.90
Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J (1982) 0.90
The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy. Am J Clin Nutr (1984) 0.90
Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts and correlation with disease expression in three generations of a kindred. Neurology (1982) 0.90
Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res (1994) 0.90